Daily Archives: August 4, 2021

Evolution in technology will improve quality of life and elevate fitness levels: Archit Aggarwal, Crossbeats – The Financial Express

Posted: August 4, 2021 at 2:25 pm

'Smart wearables have been engineered keeping in mind the wellness aspect and the kind of impact it brings into peoples lives.'(Representative image: Pixabay)

Pandemic has created a sea of change and the market landscape and every industry has been trying to cope with the change by adopting technology or upgrading its products/service to stay relevant in the market. In the consumer tech domain, we have seen that companies have been providing healthcare solutions within their product portfolio where SpO2 monitoring devices have become the talk of the town. Similarly, the sedentary lifestyle induced by the pandemic where work from home has become a norm has also motivated many to use smart devices to monitor their health in the form of multi-utility smartwatches and smart bands. In an exclusive conversation with the Financial Express Online Archit Aggarwal, Co-founder of Crossbeats shared insights on the use of technology in healthcare and about his brand Crossbeats. Excerpts:

How significant are the health metrics offered by wearables in ensuring the wellbeing of people? How has the segment evolved with regard to fitness or the pandemic?

Our smart wearables have always been engineered keeping in mind the wellness aspect and the kind of impact it brings into peoples lives. Pandemic being a dictator at the moment, our line-up of smart wearables are well equipped with modern health tracking features like Heart Rate monitor, SpO2 monitor (blood oxygen), Blood pressure monitor and scientific sleep tracker. With the steady evolution in technology, we are constantly upgrading and bringing in newer features that will improve the quality of life and help people elevate their fitness levels to fight the pandemic.

How has been the last pandemic-struck 18 months for the brand? Please share growth figures

Just like all other businesses across the world, the pandemic dealt a blow to our supply chain as well as operations. The extended lockdowns that followed the outbreak impacted the fulfilment and delivery of the products. However, as we are a consumer tech brand with focus on e-commerce, our team was quick and responsive in adapting and improvising as per the changed work environment. We made provisions for work from home for our associates, ensured all safety precautions for our operations team and partnered with the right logistics company for last-mile delivery. Our associates attended a vaccination drive so that they can stay safe. Our marketing team adapted to the need for the hour and launched a bestselling TWS Crossbeats Torq, along with a couple of more products, designed specifically for the working professionals who needed work from home products. Smart wearables were launched thereafter to provide health tracking to the consumers in the wake of the pandemic. With all these changes, we have been able to significantly grow the base business despite the challenges.

What is your strategy for the coming months to carve a niche for your products?

We understand closely what the Indian youth demands. Over the last five years, we have been able to strike the perfect balance between style and technology. In the upcoming months, we expect to increase our marketing and create a clear value proposition for our end consumers. We have plans to partner with other big distributors in order to make our products available in the offline channels as well. Our marketing team is also working on launching new products that are loaded with industry-leading features.

What new features or products can we expect from the brand?

Crossbeats R&D team along with the design experts are constantly exploring the current scenarios to understand the requirements of the modern Indian Youth. Our findings have inspired us to design and develop products on a need-based proposition, with cutting-edge technology and high-end specifications. In the coming days, the market can see Crossbeats coming up with advancements to our noise-cancelling earbuds with upgraded sound units and enhanced microphones amid other new launches. In the smartwatch category, you can expect technological upgrades like faster UI and improved health and fitness monitoring.

Brief us about the journey of Crossbeats.

The inception of Crossbeats dates back to 2015, a period when the world was getting exposed to different kinds of consumer technology while it was still in its nascent stage in India. From wired earphones to speakers, most products available in India were either international and extremely expensive or local and not at par in terms of quality. The realisation of this gap in the Indian market made me and my brother Abhinav Agarwal embark on a new journey with Crossbeats, which we envisioned as a true Indian brand that understands the new young Indians and designs tech products around their lifestyle.

Crossbeats has since then evolved from being just an audio brand to a consumer tech brand for the new Indian youth. Recently we also forayed into the wearables segment, taking into consideration the needs of the pandemic-hit world where people need to keep a real time watch on key health metrics such as blood oxygen level.

Crossbeats has been for quite some time into audio products. How has the market sentiment been? Was pandemic a factor behind your entry into the wearable segment?

As an ally to the new urban Indians, who are active, on the move and adventurous, Crossbeats has over the years created products that push the boundaries of science, art, and technology. This has resulted in Crossbeats enjoying a loyal customer base and getting the opportunity to cater to those who are passionate about our products. With over more than 5 lakh happy customers, we have had a remarkable response to our exclusive range of audio products. Our customers love the designs and the engineering that has gone into each of our products.

Be it the iconic Torq or the stylish Pebble, Crossbeats products have always been designed keeping in mind the end consumers. Crossbeats had always envisioned the growth towards active living and products being an extension of a persons lifestyle. Therefore, the segway into smart wearables was an obvious decision to create unique experiences in the intersection between lifestyle and tech that enrich peoples lives. With a genuine passion for new technologies and user-centric innovation, we wanted to provide the Indian youth with fitness, and lifestyle experience as smooth and seamless as possible.

Many players are offering similar kinds of products at similar price points, what makes your product stand out?

As a lifestyle consumer tech brand inspired by current movements in fashion, art, and music, our products are very design-centric. Our philosophy is simple and focused on providing clean aesthetics, user-friendly features, and heavy attention to detail. The unique experiences thus created through our bouquet of unique products makes us stand out of the clutter. Besides, adoption of advanced technology, frequent product launches, appealing designs and competitive pricing has allowed us to create a fan following of our brand that has only grown stronger since our inception.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know markets Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Read more:

Evolution in technology will improve quality of life and elevate fitness levels: Archit Aggarwal, Crossbeats - The Financial Express

Posted in Evolution | Comments Off on Evolution in technology will improve quality of life and elevate fitness levels: Archit Aggarwal, Crossbeats – The Financial Express

Global Nucleic Acid Isolation and Purification Market Report 2021-2031: Evolution of Biobanking in Healthcare / Capitalizing on Genetic Disorders /…

Posted: at 2:25 pm

DUBLIN, Aug. 4, 2021 /PRNewswire/ -- The "Global Nucleic Acid Isolation and Purification Market: Focus on Product, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Global Nucleic Acid Isolation and Purification Market to Reach $5,010.3 Million by 2031

The report found the nucleic acid isolation and purification market to be one of the growing markets, which is predicted to grow at a CAGR of 7.20% during the forecast period, 2021-2031.

The nucleic acid isolation and purification market growth has been primarily attributed to the major drivers in this market, such as growing number of genetic tests, increasing demand for reliable next-generation sequencing (NGS) results, rise in the prevalence of infectious diseases, increasing research funding in the field of molecular biology, and increase in awareness and acceptance of personalized medicine on a global level.

However, genomic data protection, high cost of automated instruments, and rigid regulatory standards are some of the factors expected to retrain the market growth.

The market is favored by the increased research activities based on next-generation sequencing-based technologies. The consumable segment has been segmented to into DNA and RNA sample type, among which RNA sample type is expected to growth at a highest CAGR of 7.70% during the forecast period 2021-2031. This increase is mainly attributed to the large number of research and development being conducted due to the COVID-19 pandemic, specifically considering viral RNA sample.

Within the research report, the market is segmented on the basis of product type, end users, and region. The kits segment is further segment into DNA and RNA, to gain holistic view of the industry.

Competitive Landscape

The exponential rise in the downstream application such as next-generation sequencing, polymerase chain reaction, and other techniques used for COVID-19 testing on the global level has created a buzz among companies to invest in the development of extraction RNA free severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests.

Due to technologically advanced solutions and intense market penetration, companies such as Qiagen N.V., Promega Corporation, and Thermo Fisher Scientific, Inc. have been a pioneer and a significant competitor in this market.

Key Companies Profiled

Agilent Technologies, Inc., Analytik Jena AG, AutoGen, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., Merck KGaA, Meridian Bioscience, Inc., Macherey-Nagel GmbH & Co KG, New England Biolabs, Inc, Norgen Biotek Corp., Omega Bio-tek, Inc., Orasure Technologies, Inc., PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Sage Science, Inc., Tecan Group, ThermoFisher Scientific Inc., Zymo Research

With the increasing demand for complex and custom sequencing techniques, rising genetic testing services, and growing research to treat and diagnose genetic and infectious diseases, companies have the opportunity to expand their product portfolios, increasing automation facilitation, and develop novel techniques for nucleic acid extraction by adopting different strategic approaches.

Some of the strategies followed by the contributors are new product launches and enhancements, agreements, collaborations, partnerships, acquisitions, and expansions. For instance, in 2020, Promega Corporation has launched Wizard HMW DNA Extraction Kit for researchers working with large fragments of genomic DNA, which enables researchers to obtain DNA that will provide strong performance in long-read sequencing applications in a 90-minute manual protocol.

The nucleic acid isolation and purification market has immensely propelled by nationwide sequencing activities, focusing on generating large genomic libraries for research and development purpose. For instance, Illumina, Inc. has invested $60.0 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other public and private entities.

Under the contract, Illumina, Inc. will donate next-generation sequencing (NGS) platforms, reagents, and training support worth approximately US $60 million over five years.

Key Questions Answered in this Report:

Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/ejlmbh

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original:

Global Nucleic Acid Isolation and Purification Market Report 2021-2031: Evolution of Biobanking in Healthcare / Capitalizing on Genetic Disorders /...

Posted in Evolution | Comments Off on Global Nucleic Acid Isolation and Purification Market Report 2021-2031: Evolution of Biobanking in Healthcare / Capitalizing on Genetic Disorders /…

Influence 100: ESG Will Drive Evolution Of In-House Communications Roles – PRovoke Media

Posted: at 2:25 pm

LONDON The role of the chief communications officer and chief marketing officer will evolve as a direct result of an increasing business focus on environmental, social and corporate governance (ESG) and its link with reputation, according to a survey of leading CMOs and CCOs.

Surveyed for the Influence 100,PRovoke Medias comprehensive annual report on the worlds most influential in-house communications and marketing leaders, a majority view from this years cohort expressed for the first time was that ESG would lead to a rise in prominence of the CCO function.

Among the responses outlined in the third wave of insights from the survey,published this week were: The CCO will need to lead integration of ESG across the enterprise; The role of CCO is overtaking CMO with the growing reputational, economic, environmental and social impact expectations of companies, leaders and brands; and Best-in-class chief communication officers and chief marketing officers will continue to see their responsibilities broaden and deepen as commercial and social/ESG challenges play out in a multi-stakeholder world.

The report also looks at diversity in all its facets. Diversity, equity and inclusion has continued to be a spotlight theme for the industry this year, but the research found that last years dramatic shift in what CCOs require of their PR agencies, and how committed they think the industry is to diversity, has somewhat slowed down.

In 2020, the number of respondents who agree or strongly agree that their PR agencies must have an ethnically diverse team was up from 67% in 2019 to 86%; this year, its down to 78%. Many more were neutral compared to last year, too: 16% compared to 7% in 2020. And 6% of in-house leaders a similar level to last year still disagree or strongly disagree that their agencies must have ethically-diverse teams.

There is a more stable level of conviction when it comes to whether our respondents think the communications industry is committed to recruiting, retaining and promoting people of colour: 52% agreed or strongly agreed, compared with 53% last year, compared to just 37% in 2017. A further 32% were neutral, up from 22% last year. And only 14% now think the industry is not committed to resolving issues of racial inequity, with no-one strongly disagreeing compared to 25% who disagreed or strongly disagreed last year.

When it comes to gender, theres been a worrying drop off in the number of CCOs who agree their PR agencies must have a gender-balanced account team, down from 82% last year to 73%, below 2019s figure of 77%. There were also many more neutral respondents this year, although the number who disagreed that gender balance was a requirement of their agency teams was down notably to 2% from 11% last year.

There was a slight increase in the number of our influencers who agree that the industry is committed to recruiting, retaining and promoting women, from 84% last year to 82%. A further 16% took a neutral position, with only 2% saying they disagreed with this statement and no-one saying they strongly disagreed.

We also asked our Influence 100 to delve deeper this year, and come up with practical suggestions for what the PR industry could actually do to improve diversity, equity and inclusion. Two areas of focus stood out in the responses: recruitment in general, and bringing younger people from more diverse backgrounds into the industry.

One respondent eloquently summed up the complexity of the issue: Businesses cannot solve the problems of today or tomorrow with a mindset of the past. With regard to diversity, equity and inclusion in PR, just do it! For the sake of innovation and relevance, cultivate and appoint leadership and account teams who have the cognitive diversity that comes from a fierce combination of the diversity you can see and the diversity you must inquire about (life experience, problem-solving style, barriers successfully overcome in life experience, leadership style). The two types of diversity are inter-related and invaluable for crafting teams and solutions that break convention and result in a competitive advantage.

When we asked our respondents more generally about their predictions for the future of the CCO and CMO roles within businesses, the responses were largely aligned. Many, as in previous years, feel that there will be more integration and a blurring of the two roles.

The survey also provides insights into the greatest communications challenges they and their organisations are facing in lockdown. The top two responses cited by 60% of respondents were workplace disruption, up from 49% last year, and staff health and wellbeing, up from 46% in 2020. Other concerns were travel and movement restrictions, customer disruption, sales and earnings, misinformation and layoffs.

Profiles of the Influence 100 can be found here, including Q&As from many of this year's list. Insights into their demographics and background here; and research into budgets and how they manage agencies are here.

Continued here:

Influence 100: ESG Will Drive Evolution Of In-House Communications Roles - PRovoke Media

Posted in Evolution | Comments Off on Influence 100: ESG Will Drive Evolution Of In-House Communications Roles – PRovoke Media

Show Me Missouri: The evolution of music in the Ozarks – KOLR – OzarksFirst.com

Posted: at 2:25 pm

SPRINGFIELD, Mo. The world can thank Missouri for developing some of the countrys and the worlds biggest musical acts. And before KOLR was KOLR, we were KTTS: The areas first television station and sister station to one of the most popular country music stations around. So settle back and enjoy this look at Missouris musical legacy.

When we go back to the roots of Missouri music, theres no better expert to call on than long-time radio host Wayne Glenn. Hes like a walking encyclopedia of music and Missouris role in shaping it.

So, what makes Ozarks music unique?

According to Glenn, If we talk about 200 years of America, Missouri, the Ozarks, and we start talking about Ozarks music, then, of course, the Irish and the scotch-Irish, all the different groups. They brought their instruments with them when they came in the 1830s, and 40s, and 50s, and 60s. And the heritage began there and has continued right on until the days of Branson, the Ozark Jubilee in the 1950s and 60s, the Ozark Mountain Daredevils, Big Smith, Tom Whitlocks composition, Take My Breath Away, which was an academy award-winning song written by an Ozarker. Its just one thing after another. We have this wonderful mixture of fiddles (call them violins, if you want to be technical), banjos, the jews harp, the harmonica, and the guitar. And, the traditions of American families here in the Ozarks getting together around an organ or a piano with the stringed instruments and just having fun playing and singing.

And when you talk about Ozarks music, Wayne says theres one form in particular that made southwest Missouri a mecca.

The most famous style of Ozark music, from a professional angle, would be country, said Wayne. Theres no doubt about that. And it all began, really, as far as the money part, with fiddlers getting paid on Saturday night to play at a square dance. And that would even be back in the 1800s. There were fiddlers who were known in their community to be good, and they would be paid. Not much, but some little amount of money. Then you come to the radio. When commercial radio came to the Ozarks, well, in this case, KWTO, KGBX Springfield in 1932/1933, then they began, those musicians, the Slim Wilsons, the Speedy Haworth, the Goodwill Family, the Hayden family, Lonnie and Thelma, all those namesthey began to be paid to be on the radio.

Ozarks radio led the way with nationally syndicated live music from its legendary radio stations, one of which, KTTS, had a future game show host as its DJ. At the time, the price, and the gig, were right for Drury University Alum Bob Barker.

But soon, Springfield was knocking on Nashvilles door as a country music centerpiece, with acts like Eddy Arnoldstill the artist with the most top 10 country songs in historyhosting a national T.V. variety show from Springfields Jewell Theatre.

Eddy, when he first became famous in Nashville, back in the mid-to-late 1940s, he did a syndicated radio show that was put together by Charlie Brown and Jim Brown, said Wayne. The Brown Brothers were from Springfield. They were working in Nashville in the late 40s. So then, in the 50s, when it became a possibility that Springfield might become an important venue for lots of network shows, then the Browns came back to Springfield and they approached Eddy Arnold about doing a T.V. show from the Jewell Theatre as part of the Radiozark, which is the company that owned the Jubilee and the Jewell concept. He came. Eddy came.

Arnold came and went, and so did Springfields musical dominance. Soon Branson, led by entertainers like Ray Stevens and Andy Williams, would remake Ozarks musical image for a new generation.

You know the story is Ray Stevens was already here, said Wayne. Well when ray stevens came in the 1980s/early 1990s, ray stevens was a bigger entertainer, as far as hits, than andy Williams was. Andy was very well known, but his heyday of hit records was over. Ray Stevens was still going well. Ray stevens manager was andy Williams brother. And ray stevens managerthat brothertold brother Andy this is where you need to come to continue your fame and fortune. And thats what andy did.

And while its unclear whats next for music in the Ozarks, the region will always have a sweet-sounding legacy to celebrate.

Read the original here:

Show Me Missouri: The evolution of music in the Ozarks - KOLR - OzarksFirst.com

Posted in Evolution | Comments Off on Show Me Missouri: The evolution of music in the Ozarks – KOLR – OzarksFirst.com

EQUUS Evolution Tickets on Sale – Thoroughbred Daily News

Posted: at 2:25 pm

Wednesday, August 4, 2021 at 2:02 pm | Back to: Top News

Updated: August 4, 2021 at 2:21 pm

Tickets for the EQUUS Evolution theatrical performance, the evening showcase of the EQUITANA USA trade fair and expo, are on sale now at http://www.equitanausa.com. The performances will be held in Alltech Arena at the Kentucky Horse Park Oct. 1-3.

The 90-minute performance will include appearances from performing arts trainer and championship competitor Mario Contreras with special appearances include the American Vaulting Association's Lynn Palm and Nic Roldan. Highlighting the artistic vision of Chanel Rhodes, select performances at the evdent will include unique equine attire.

The full EQUITANA USA day programming includes exhibitions, educational and performance content, as well as the full trade show and marketplace of equine industry products and services.

Tickets for the full EQUITANA USA show are $27 (ages 13+), $10 (ages 6-12), and free for children five and under and include on-site parking, free United States Equestrian Federation fan membership and admission into the Kentucky Horse Park, which includes access to the International Museum of the Horse, American Saddlebred Museum and Hall of Champions.

For more information about EQUITANA USA, also visit http://www.kyhorsepark.com.

Not a subscriber? Click here to sign up for the daily PDF or alerts.

This story was posted in Top News and tagged Alltech Arena, EQUITANA, Equitana USA, EQUUS Evolution, Kentucky Horse Park, tickets on sale, trade fair and expo.

Continued here:

EQUUS Evolution Tickets on Sale - Thoroughbred Daily News

Posted in Evolution | Comments Off on EQUUS Evolution Tickets on Sale – Thoroughbred Daily News

Jamie Carragher hoping Reds’ evolution will provide opportunities for youngsters – BT Sport

Posted: at 2:25 pm

Liverpools evolution of their squad should provide more opportunities for youngsters Curtis Jones and Harvey Elliott, according to former defender Jamie Carragher.

The departure of Georginio Wijnaldum, 31 in November, at the end of last season has drawn criticism from a section of fans concerned at the loss of the clubs most consistent and reliable midfielder.

However, with a significant number of the squad which won the 2018-19 Champions League and 2019-20 Premier League titles aged 29 or over, there is a need to gradually introduce new blood to reduce the age profile.

A new contract for Fabinho on Tuesday, following on from Trent Alexander-Arnolds four-year deal, with the likes of Alisson Becker, Mohamed Salah, Virgil Van Dijk and Sadio Mane also set to get extensions, is part of the long-term planning.

But the process of refreshing the squad has already begun with the arrival of 22-year-old centre-back Ibrahima Konate this summer and Diogo Jota, 24, last year.

It also offers greater opportunity for the likes of 20-year-old Jones and 18-year-old Elliott, who impressed last season on loan at Blackburn but, the PA news agency understands, will not be allowed to leave again as his integration into the first-team squad will begin in earnest.

You want the team to evolve. You dont want drastic change, revolution, and seven players have to go out because theyve all come to the end at the same time, Carragher, speaking at a Soccer Aid event, told PA.

You want Wijnaldum to stay but I can understand it from the clubs point of view as well: there are a lot of players in that midfield getting to that age and maybe you want younger blood; more room for Curtis Jones, maybe, who is another player who will come in.

I can understand it from both situations but there are a lot of players at that stage of two years to go with Liverpool around that 28-to-30 mark and we have possibly seen the first two or three of that (rejuvenation) with Jota and Konate coming in.

I think there maybe one more before the window closes but over the next couple of years we will have to see a few more and that gradual evolving of that great Jurgen Klopp team will come to an end and hopefully he will be able to create another one before he goes.

With another 29-year-old, Xherdan Shaqiri, expected to depart before the end of the transfer window, another place in the squad will be freed up and Carragher believes Elliott is a perfect fit.

He was outstanding last season, one of the best players in the Championship for such a young lad, he added.

I actually see Harvey coming in and taking the place of Shaqiri, really, who I think will move on, and he (Elliott) will have that role in the squad.

It is interesting in pre-season he has played more central midfield than part of the front three because its always going to be difficult being a right-sided attacking player with a left foot when you have Mo Salah in front of you but he will get opportunities.

He is a player of huge quality and I am sure he is going to have a massive Liverpool future and, when you have someone who has that quality, it doesnt matter about his age, you have to give them their head.

Id imagine Harvey Elliott will be getting 15 to 20 games this season.

:: Soccer Aid for UNICEF 2021 takes place on Saturday September 4 at the Etihad Stadium. The money raised from this years game will help UNICEF fight back against the Covid-19 pandemic by helping to deliver two billion vaccines worldwide. Tickets are available at: http://www.socceraid.org.uk/tickets

See the original post:

Jamie Carragher hoping Reds' evolution will provide opportunities for youngsters - BT Sport

Posted in Evolution | Comments Off on Jamie Carragher hoping Reds’ evolution will provide opportunities for youngsters – BT Sport

Evolution of automotive glazing in India: Impact of pandemic and road ahead – Financial Express

Posted: at 2:25 pm

Image for representational purposes

Covid-19 and impact on the automotive glazing industry: The Automotive industry, with its multi-layered global supply chain, was significantly impacted due to the pandemic. In the year 2020, the one-month nationwide lockdown brought the industry to a standstill. However, due to the pent-up demand and increased need for personal mobility the industry recorded strong volumes in the last quarter of 2020.

The Indian automotive glazing industry was also affected due to fluctuation in demand. The other factor which had an impact is the depreciation of the Indian Rupee as many key input materials still need to be imported. Logistics of getting components for various regions became a challenge due to restrictions in the country of origin, lack of regular connectivity and movement on various locations by road. The pandemic also forced the auto component industry to look for alternate sources and put import substitution on top priority.

Regional lockdowns impacted the distribution and retailing of glass directly impacting the replacement glass business. However, this segment recorded a strong demand as soon as the restrictions were eased.

Improvement in the glazing processes over the last decade

The automotive industry requires two types of glasses in an automobile, a laminated windshield for the front and tempered glass for the sides and rear to meet the safety regulations.

The laminated windshield provides protection against external impacts ranging from a small stone to even accidents. Technically laminated glass consists of two layers of strengthened glass sandwiched by a plastic interlayer, called PVB that acts as a safety layer that holds on to the glass even after shattering.

The tempered glasses for the sides and the rear provide safety by their mere strength and the ability to shatter into small pieces without any sharp edges. The toughening process involves heating of annealed glass just above 600C and the surfaces are rapidly cooled to create compression on the outer surface and tension on the inside. This causes residual stresses and makes the toughened glass stronger by 6 times the normal annealed glass and provides the same visible light transmission.

Automotive glazing has become thinner to reduce the overall weight of the vehicle. This helps in improving mileage and thus contributes to the reduction in carbon footprint. A significant weight reduction of 25-30% can be achieved by using thinner glass without compromising the safety requirement.

The color of the glasses has changed from clear to green and solar control green. These glasses help in reducing the heat coming inside the car offering better comfort to the user. The reduction in heat coming inside the vehicle minimizes the load on air conditioning and further improves fuel efficiency. Some of the export models also have privacy glasses, which are legally permitted in many regions outside India.

The glazing normally cuts noise entering the vehicle cabin but in recent years the acoustic comfort is enhanced by special laminated glasses and encapsulated side glasses. These new technologies improve acoustic comfort inside the cabin for better conversation or noise-free listening of the audio system.

Next decade will be an inclination towards EV

India has recognized that EVs hold immense potential in reducing pollution and dependency on imported petroleum products. The policies, regulations and subsidies are progressing towards the adoption of Electric Vehicles in the coming years. As EVs are different from a conventional IC engine vehicle at the fundamental level in terms of design, performance, durability and safety there is also a very different expectation on the automotive glazing side. The glazing of a typical electric vehicle is expected to add more features and improve driving comfort more than just a structural and a safety-critical part.

Electric vehicles not only provide reduced energy dependence and less maintenance but also focusses on several driving comfort features. Advanced Driver Assistance System (ADAS) is one of the major emerging technology that addresses driving comfort and increases car and road safety. The ADAS use automated technology, such as sensors and cameras, to detect nearby obstacles or driver errors, and respond accordingly.

Thermal comfort is even more important in an EV and in order to achieve higher thermal efficiencies, coated glazing is being used. A special metallic coating reflects out the heat while allowing the visible part of the light to pass through, resulting in superior performance.

Most of the sensors like rain-light-sensor (RLS) are housed at the top of the windshield. Cameras and Lidar also can be integrated into the windshield, which would protect them from the external environment and at the same time giving them a view very similar to that of the driver.

Another important development is the HUD (Head-up Display) which allows the driver to get information and navigational support right in front without taking his eyes off the road. Higher costs have limited this technology to the luxury segment, however, with improvement in technology and scale HUD will start becoming popular in all segments. With the integration of electronics into glazing systems, several exciting applications can be expected in the coming years.

Author: Venu Shanbhag, Managing Director (Sekurit), Saint-Gobain India

Disclaimer: The views and opinions expressed in this article are solely those of the original author. These views and opinions do not represent those of The Indian Express Group or its employees.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs,calculate your tax by Income Tax Calculator, know markets Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

See the article here:

Evolution of automotive glazing in India: Impact of pandemic and road ahead - Financial Express

Posted in Evolution | Comments Off on Evolution of automotive glazing in India: Impact of pandemic and road ahead – Financial Express

Stage IV lung cancer patient enjoys life extension from targeted therapy treatments – Loma Linda University Health

Posted: at 2:25 pm

Ongoing advances in treatment options for patients with lung cancer are spurring patients hopes for life extensions in the face of the nations deadliest cancer. In honor of this years upcoming World Lung Cancer Day, medical oncologist Hamid Mirshahidi, MD, from Loma Linda University Cancer Center, and patient Maribel Padilla spread the word about a type of promising treatment option available to those living with lung cancer.

Though chemotherapy tends to come to mind first as the conventional route for cancer treatment, a slew of targeted therapies perpetually emerging from research and clinical trials are capable of outperforming chemotherapy in groups of patients with specific genetic mutations, Mirshahidi says.

Such was the case for 55-year-old Maribel Padilla, who, before reaching Loma Linda University Health in 2011, was informed she had a year maximum to live with stage four lung cancer that spread to her brain. After undergoing a brain surgery at the initial institution, Padilla transferred to LLU to work with the Cancer Center team and enrolled in three clinical trials. She has celebrated a decade of life since.

Our mindset was to give it a shot because we thought our mom had less than a year to live and we had nothing to lose. Gabriela Castillo

To determine whether Padilla would benefit from targeted therapy, LLU cancer experts conducted a tissue biopsy and analyzed her DNA. Sure enough, Padilla possessed a mutation in the DNA called anaplastic lymphoma kinase (ALK), placing her among the roughly 25% of lung cancer patients with any oncology driver mutation and qualifying her for enrollment in some clinical trials, Mirshahidi said.

Of that 25%, Padilla was among the 5% of patients with ALK specifically a DNA mutation in lung cells that happens when two genes fuse, prompting lung cells to make too many copies of themselves that are cancerous and prone to spread throughout the body.

Padilla and her daughters, Gabriela and Karla Castillo, learned about the clinical trials and ultimately took the leap of faith to enroll. Our mindset was to give it a shot because we thought our mom had less than a year to live and we had nothing to lose," Gabriela said.

Padilla first enrolled in a trial for the drug Crizatinib and experienced minimal side effects. Yet, as lung cancer mutates and moves throughout the body, it may become resistant to one drug and weak to another. Cognizant of this phenomenon, LLU Cancer Centers weekly multidisciplinary team quickly and repeatedly tests for patients mutations and adapts treatment to a new targeted therapy drug.

After about a year on the first drug, Padillas cancer spread to her brain a second time, and her care team promptly enrolled her in a new clinical trial for a drug called Ceratinib. She continued this treatment regimen for years to keep the cancer under control and again experienced minimal adverse reactions relative to what chemotherapy tends to induce.

Ms. Padilla was able to benefit from and prove that those targeted therapy drugs for lung cancer patients with her same mutations are much more beneficial than chemotherapy would have been.Dr. Hamid Mirshahidi

Most recently, Padilla started on Lorlatinib through compassionate use, which occurs when a pharmaceutical company grants a clinical center the ability to provide their patients with a non-FDA-approved drug. Since Padilla completed the clinical trials and started compassionate use, all three targeted therapies have been FDA-approved.

To earn FDA approval, targeted therapies must prove themselves more effective than conventional chemotherapy for a specific group of patients, Mirshahidi said. After one targeted therapy obtains approval, usually a newly created, more potent drug will require another clinical trial, and so on.

Mirshahidi says targeted therapy produces fewer side effects for patients who meet the genetic criteria, proves more thorough and effective for fighting cancer, and offers a better quality of life than traditional chemotherapy. He continues to monitor Padillas response to treatment via various tests like CT scans and MRIs, which show shrinkage of her cancer.

She is now about eight years into treatment with no evidence of recurrence and never tried any conventional IV chemotherapy at LLU, he said. Ms. Padilla was able to benefit from and prove that those targeted therapy drugs for lung cancer patients with her same mutations are much more beneficial than chemotherapy would have been.

Since starting targeted therapy for her lung cancer, Padilla says she has felt grateful to live these past 10 years, during which she met her five newly-born grandchildren and solidified her pre-existing bonds with her other grandchildren.

Meanwhile, advances in targeted therapies forge ahead full-speed while Loma Linda University Heath continues to enhance and hone life-changing treatment plans to optimize lung cancer patients health journeys.

At Loma Linda University Cancer Center, physicians are committed to providing patients with compassionate, comprehensive care that gives them the best opportunity to face and overcome cancer. To learn more about lung cancer care at the Cancer Center, please visit lluh.org/cancer-center/cancer-programs/lung-cancer-care.

View original post here:

Stage IV lung cancer patient enjoys life extension from targeted therapy treatments - Loma Linda University Health

Posted in Life Extension | Comments Off on Stage IV lung cancer patient enjoys life extension from targeted therapy treatments – Loma Linda University Health

J&J says U.S. FDA agrees to extend shelf life of its COVID-19 vaccine – Reuters

Posted: at 2:25 pm

Empty vials of Johnson & Johnson's coronavirus disease (COVID-19) vaccine are seen on a table at a vaccination centre in Ronda, Spain, April 23, 2021. REUTERS/Jon Nazca/File Photo/File Photo

July 28 (Reuters) - The U.S. Food & Drug Administration extended the shelf life for Johnson & Johnson's (JNJ.N) single-shot COVID-19 vaccine to six months from four-and-a-half months, the company said late Wednesday.

The FDA's decision is based on data from ongoing studies, which showed the vaccine is stable at six months when refrigerated at 2 to 8 degrees Celsius (3646 degrees Fahrenheit), the drugmaker said. (https://bit.ly/3ypgpTT)

In a letter to the company, the FDA said it had completed the review of data provided by J&J, and based on the information submitted, it concurs with the extension. (https://bit.ly/3zRuTMB)

The agency also said the extension was applicable to batches that might have expired prior to the issuance of the letter provided they were stored at the recommended temperature.

Reporting by Aakriti Bhalla in Bengaluru; Editing by Shinjini Ganguli and Subhranshu Sahu

Our Standards: The Thomson Reuters Trust Principles.

Read this article:

J&J says U.S. FDA agrees to extend shelf life of its COVID-19 vaccine - Reuters

Posted in Life Extension | Comments Off on J&J says U.S. FDA agrees to extend shelf life of its COVID-19 vaccine – Reuters

Major UK trial to assess whether cannabis-based drug could extend life for thousands with aggressive brain tumours – The Brain Tumour Charity

Posted: at 2:25 pm

The new phase II trial, to be funded by The Brain Tumour Charity, will assess whether adding Sativex (an oral spray containing cannabinoids THC and CBD) to chemotherapy could extend life for thousands with a recurrent glioblastoma.

The drug -already used in treating multiple sclerosis -was found to be tolerable in combination with chemotherapy, with the potential to extend survival, in a phase I trial in glioblastomas earlier this year.

The new three-year phase II trial (ARISTOCRAT), led by Professor Susan Short at the University of Leeds and co-ordinated by the Cancer Research UK Clinical Trials Unit at the University of Birmingham, is due to begin recruiting over 230 patients across all UK nations in early 2022, subject to sufficient funds being raised.

Having seen its income drop by over 25% last year due to the pandemic and been forced to pause its regular research grant funding programme, The Brain Tumour Charity has today launched an appeal to raise the 450,000 needed to open the trial as soon as possible.

Experts hope that, should the trial prove successful, Sativex could represent one of the first additions to NHS treatment for glioblastoma patients since temozolomide chemotherapy in 2007.

Glioblastomas are the most common and most aggressive form of brain cancer, with around 2,200 people diagnosed each year in England alone. They are usually fast-growing and diffuse, with poorly-defined boundaries and thread-like tendrils that extend into other parts of the brain.

Almost all glioblastomas recur even after intensive treatment including surgery, radiotherapy and chemotherapy, and average survival is just 12-18 months from first diagnosis.

Over the last decade, there has been significant global interest within both patient and scientific communities about the activity of cannabinoids in brain tumours, with the view that cannabinoid-based products may not only help relieve symptoms but could also have a positive impact on survival.

Several pre-clinical laboratory studies have suggested that cannabinoids THC and CBD may reduce brain tumour cell growth and could disrupt the blood supply to tumours -however, to date, clinical evidence that they could treat brain tumours has been limited.

In this new phase II trial, researchers will assess whether adding Sativex to the current standard chemotherapy treatment (temozolomide) could offer extra time to live for adults diagnosed with a recurrence of their glioblastoma after initial treatment.

The trial plans to recruit 232 participants across a minimum of 15 hospitals: two thirds of the participants will be given temozolomide plus Sativex, while one third will be given temozolomide plus placebo.

Sativex, manufactured by GW Pharma, is an oromucosal spray containing 1:1 THC (Delta-9-tetrahydrocannabinol) and CBD (cannabidiol), with the active ingredients being absorbed in the lining of the mouth, either under the tongue or inside the cheek.

Participants will be asked to administer up to 12 sprays per day (or to the maximum dose they can tolerate if fewer than 12) of Sativex or placebo oral sprays.

Participants will then undergo regular follow-up including clinical assessment (every four weeks), blood tests, MRI scans (every eight weeks), and they will complete quality of life questionnaires. This will also be one of the first trials to integrate with The Brain Tumour Charitys app BRIAN.

The trial will measure whether adding Sativex to chemotherapy extends the overall length of patients lives (overall survival), delays the progression of their disease (progression-free survival) or improves quality of life.

In the initial phase I study, the most common side-effects reported were fatigue, headache, vomiting and nausea, which were mostly classed as being mild-moderate in severity.

Stephen Lee, 62 from Leyland in Lancashire, took part in the phase I trial of Sativex in 2015 after his glioblastoma returned following initial treatment. Stephen was first diagnosed in 2010, just a few months after he had very sadly lost his older brother to the same disease. Stephen said:

My diagnosis was very sudden and was one of those days you never forget. Having had to leave work early with a severe headache and a stabbing pain in my right eye, my wife insisted that we go straight to hospital after what my brother had experienced.

I was admitted that same day, had a scan and thats when they identified it was a brain tumour. I had the operation the following week, and beforehand my wife and I agreed that we wanted to stay positive, to keep living our lives and to enjoy however much time we had together.

I joined the early trial of Sativex in the hope that it could improve my quality of life, but I also thought it was important to do so as the chemotherapy and radiotherapy I was having had all been trialled by other people before it could be used safely. I thought it only right and proper that I followed in their footsteps and joined a trial to help prove a new drug which could benefit so many people in the future with a recurring glioblastoma.

I took the oral spray 10 times a day, and it was easy as I could take it wherever we were going, even while out for dinner. While I dont know whether I had Sativex or the placebo, since the trial finished in 2016, all my MRI scans have been clear.

"This new trial is so important as it will give people hope that there could be life beyond a glioblastoma diagnosis and that there are other treatments being trialled to support them to live their lives.

Principal Investigator, Professor Susan Short, Professor of Clinical Oncology and Neuro-Oncology at the University of Leeds, said:

The treatment of glioblastomas remains extremely challenging. Even with surgery, radiotherapy and chemotherapy, nearly all of these brain tumours re-grow within a year, and unfortunately there are very few options for patients once this occurs.

Cannabinoids have well-described effects in the brain and there has been a lot of interest in their use across different cancers for a long time now. Glioblastoma brain tumours have been shown to have receptors to cannabinoids on their cell surfaces, and laboratory studies on glioblastoma cells have shown these drugs may slow tumour growth and work particularly well when used with temozolomide.

Its really exciting that were now at the point where we can run a definitive, well-designed study that will tell us the answer to whether these agents could help treat the most aggressive form of brain tumour. Having recently shown that a specific cannabinoid combination given by oral spray could be safely added to temozolomide chemotherapy, were really excited to build on these findings to assess whether this drug could help glioblastoma patients live longer in a major randomised trial.

Dr David Jenkinson, Interim CEO at The Brain Tumour Charity, which is funding the trial, said:

We hope this trial could pave the way for a long-awaited new lifeline that could help offer glioblastoma patients precious extra months to live and make memories with their loved ones.

With so few treatments available and average survival still so heartbreakingly short, thousands affected by a glioblastoma in the UK each year are in urgent need of new options and new hope.

We know there is significant interest among our community about the potential activity of cannabinoids in treating glioblastomas, and were really excited that this world-first trial here in the UK could help accelerate these answers. The recent early-stage findings were really promising and we now look forward to understanding whether adding Sativex to chemotherapy could help offer life-extension and improved quality of life, which would be a major step forward in our ability to treat this devastating disease.

But we also know that for many, this trial wont come soon enough. In the meantime, while other cannabis-based products may help alleviate symptoms, there is insufficient evidence to recommend their use to help treat brain tumours. For anyone considering using cannabis-based products or other complementary therapies, its vital that you discuss these with your medical team first, as they could interact with other treatments such as anti-epileptic medicines or steroids.

Anyone affected by a glioblastoma can speak to us for support and information on 0808 800 0004 or by emailing support@thebraintumourcharity.org. If you need someone to talk to, were here for you.

Professor Pam Kearns, Director of the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham, which is co-ordinating the trial, said:

Our mission at the CRCTU is to translate cutting-edge science and research into improved patient care by identifying novel therapies that will save lives. It is vital that trials like this, investigating the role cannabis or the chemicals in it can play treat cancer, are carried out.

Read the original:

Major UK trial to assess whether cannabis-based drug could extend life for thousands with aggressive brain tumours - The Brain Tumour Charity

Posted in Life Extension | Comments Off on Major UK trial to assess whether cannabis-based drug could extend life for thousands with aggressive brain tumours – The Brain Tumour Charity